Published in Vaccine Weekly, December 25th, 2002
"Because the prognosis of patients with pancreatic cancer is very poor, development of a novel approach for treatment of this disease is vital," commented Yasuto Akiyama and colleagues at the National Cancer Center Research Institute in Japan and the National Cancer Institute in the United States.
The investigators used the HPD1NR hamster pancreatic cancer model to test the ability of a DC-based vaccine to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly